ClinicalTrials.Veeva

Menu
D&H National Research Centers | Cancer Research Center logo

D&H National Research Centers | Cancer Research Center

Research site

Site insights

Top conditions

Top treatments

Docetaxel
Ritonavir
Folate
Panitumumab
ALK202
Methylthioadenosine
Sasanlimab
DB-1305
Bevacizumab
MTA

Parent organization

This site is a part of D&H National Research Centers

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Alexander Chacin

Verified by this site

Active trials

14 of 16 total trials

A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tol...

Enrolling
Advanced Solid Tumor
Drug: LAT010
Drug: LAT010 + ICI

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced maligna...

Enrolling
Hodgkin Lymphoma
Malignant Melanoma
Drug: CTX-8371

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced sol...

Enrolling
HER2-positive Advanced Solid Tumor
Drug: Itraconazole
Biological: DB-1303/BNT323

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or re...

Enrolling
Advanced MTAP-null Solid Tumors
Drug: Comparator AMG 193 Test Tablet
Drug: Docetaxel

The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovar...

Enrolling
Refractory Ovarian Carcinoma
Platinum-resistant Ovarian Cancer
Drug: CBX-12

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumo...

Enrolling
Advanced Solid Tumor
Drug: Trastuzumab
Drug: DB-1310

TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the...

Enrolling
Advanced Cancer
Advanced Solid Tumor
Drug: ALK202

This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelv...

Enrolling
COVID-19 Infection
Drug: remdesivir
Drug: placebo for ibuzatrelvir

The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R ver...

Enrolling
Myelodysplastic Syndromes
Biological: Epoetin Alfa
Biological: Luspatercept

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced sol...

Enrolling
Advanced Solid Tumor
Drug: DB-1305/BNT325
Drug: BNT327

The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patien...

Enrolling
Non Small Cell Lung Cancer
Drug: Gotistobart
Drug: Docetaxel

This Phase 1/2a study will explore the safety and efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) activator, used alone or in combination with anti-PD...

Enrolling
Locally Advanced or Metastatic Solid Tumors
Drug: Combination of PTT-936 and anti-PD-1/L1 therapy
Drug: PTT-936
Locations recently updated

The aim of this study is to compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal ca...

Enrolling
Metastatic Colorectal Cancer
Drug: FOLFIRI Regimen
Drug: Bevacizumab-awwb

The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vin...

Enrolling
Large B-cell Lymphoma
Drug: Golcadomide
Drug: Doxorubicin

Trial sponsors

D
Amgen logo
Pfizer logo
Bristol-Myers Squibb (BMS) logo
Celgene logo
C
C
E
L
O

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems